405554-54-3 Usage
Molecular structure
1H-Inden-1-one, 5-[2-[4-[2-(diMethylaMino)ethoxy]phenyl]-5-(4-pyridinyl)-1H-iMidazol-4-yl]-2,3-dihydrocontains a complex structure with indenone (a five-membered ring), a substituted imidazole ring, and a dimethylaminoethoxy group.
Indenone presence
The compound contains indenone, which is a five-membered ring structure that is commonly found in various drugs and bioactive compounds.
Substitution on imidazole ring
The compound features a substituted imidazole ring, which is another structural component that is prevalent in many pharmacologically active compounds.
Potential pharmacological activities
Due to the presence of the imidazole and indenone moieties, 1H-Inden-1-one, 5-[2-[4-[2-(diMethylaMino)ethoxy]phenyl]-5-(4-pyridinyl)-1H-iMidazol-4-yl]-2,3-dihydromay exhibit a range of pharmacological activities, although further research is needed to fully understand its properties and potential uses.
Biological activities
The compound may have biological activities due to the presence of various functional groups and structural components, which are commonly found in bioactive compounds.
Need for further research
The properties and potential uses of 1H-Inden-1-one, 5-[2-[4-[2-(diMethylaMino)ethoxy]phenyl]-5-(4-pyridinyl)-1H-iMidazol-4-yl]-2,3-dihydroare not yet fully understood, and additional research is necessary to explore its potential applications in the field of pharmacology and biology.
Check Digit Verification of cas no
The CAS Registry Mumber 405554-54-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,5,5,5 and 4 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 405554-54:
(8*4)+(7*0)+(6*5)+(5*5)+(4*5)+(3*4)+(2*5)+(1*4)=133
133 % 10 = 3
So 405554-54-3 is a valid CAS Registry Number.
405554-54-3Relevant academic research and scientific papers
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds
Niculescu-Duvaz, Dan,Niculescu-Duvaz, Ion,Suijkerbuijk, Bart M.J.M.,Ménard, Delphine,Zambon, Alfonso,Nourry, Arnaud,Davies, Lawrence,Manne, Helen A.,Friedlos, Frank,Ogilvie, Lesley,Hedley, Douglas,Takle, Andrew K.,Wilson, David M.,Pons, Jean-Francois,Coulter, Tom,Kirk, Ruth,Cantarino, Neus,Whittaker, Steven,Marais, Richard,Springer, Caroline J.
experimental part, p. 6934 - 6952 (2010/11/03)
V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) is a serine/threonine-specific protein kinase that is mutated with high frequency in cutaneous melanoma, and many other cancers. Inhibition of mutant BRAF is an attractive therapeutic approach for the treatment of melanoma. A triarylimidazole BRAF inhibitor bearing a phenylpyrazole group (dimethyl-[2-(4-{5-[4-(1H-pyrazol-3-yl)-phenyl]-4-pyridin-4-yl-1H-imidazol-2-yl} -phenoxy)-ethyl]-amine, 1a) was identified as an active BRAF inhibitor. Based on this starting point, we synthesized a series of analogues leading to the discovery of 6-{2-[4-(4-methyl-piperazin-1-yl)-phenyl]-5-pyridin-4-yl-3H- imidazol-4-yl}-2,4-dihydro-indeno[1,2-c]pyrazole (1j), with nanomolar activity in three assays: inhibition of purified mutant BRAF activity in vitro; inhibition of oncogenic BRAF-driven extracellular regulated kinase (ERK) activation in BRAF mutant melanoma cell lines; and inhibition of proliferation in these cells.
Imidazole derivatives as raf kinase inhibitors
-
, (2008/06/13)
Novel compounds (I) and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy wherein Ar is a group of formula a) or b).
